Valerie Baia

"Located deep in the heart of Europe, home to some of the world's most important international health institutions as well as two of its largest pharmaceutical companies in Novartis and Roche, and with a number one ranking globally in terms of ease of doing business and innovation; Switzerland can truly lay claim to be a healthcare and life sciences powerhouse. Despite some of the highest operating costs of any country in the world, an increasing number of pharma companies are choosing to base… Mehr anzeigen

"Located deep in the heart of Europe, home to some of the world's most important international health institutions as well as two of its largest pharmaceutical companies in Novartis and Roche, and with a number one ranking globally in terms of ease of doing business and innovation; Switzerland can truly lay claim to be a healthcare and life sciences powerhouse. Despite some of the highest operating costs of any country in the world, an increasing number of pharma companies are choosing to base their European and EMEA headquarters in Switzerland, allowing the landlocked nation of merely eight million to firmly establish itself as 'Europe's brain.'" - report excerpt Weniger anzeigen

"With a population of just 4.7 million and a landmass smaller than the state of Indiana on the edge of Europe, the Republic of Ireland stands as an unlikely pharmaceutical manufacturing powerhouse. Dating back to a decision made in the 1960s to target the sector as a strategic industry, today Ireland ranks as the largest net exporter of pharmaceuticals in the European Union (EU) and seventh largest in the world." - report excerpt

"Most people's perceptions of what the locals fondly refer to as 'Sonderfall Schweiz' ('special case Switzerland') conjure up images of an adamantly neutral country with a fiercely independent streak, of chocolate box architecture, cuckoo clocks, snowy mountain peaks, the G-rated Matterhorn and jewel-bedazzled glitterati. What is all too often overlooked, however, is the country's formidable pedigree as a pharmaceuticals powerhouse and hotbed of scientific innovation." - report excerpt

"With the roots of its history sewn into a constantly evolving narrative, South Africa, under democratic rule, has undergone a remarkable transition through the implementation of sweeping social and macroeconomic reforms. Institutional advancements have practically touched every fabric of society to produce a truly transformative and growth-driven state. With a population of 54 million and GDP of roughly USD 350 billion, the country is one of the largest economies in Africa—second only to… Mehr anzeigen

"With the roots of its history sewn into a constantly evolving narrative, South Africa, under democratic rule, has undergone a remarkable transition through the implementation of sweeping social and macroeconomic reforms. Institutional advancements have practically touched every fabric of society to produce a truly transformative and growth-driven state. With a population of 54 million and GDP of roughly USD 350 billion, the country is one of the largest economies in Africa—second only to Nigeria—and leads the continent in broad-based industrial development, while also consequently serving as a strategic hub for many companies' pan-African operations." - report excerpt Weniger anzeigen

"Once touted by the IMS as one of the "fast followers" among the world's "pharmerging" nations and feted by the international investor community in the wake of EU accession, Romania's pharmaceutical industry appears resurgent once more after a number of years on the back burner." - report excerpt

"Though traditionally recognized for its pioneering efforts in industries such as electronics, shipping and automotive, Korea has taken advantage of its newfound global economic competitiveness to embrace pharma head on. Through government initiatives designed to promulgate growth in the pharmaceutical and biotech sectors, the country aims to become a top seven player and to create 20 new drugs by 2020 according to their Pharma Vision 2020.

The race for innovative competitiveness… Mehr anzeigen

"Though traditionally recognized for its pioneering efforts in industries such as electronics, shipping and automotive, Korea has taken advantage of its newfound global economic competitiveness to embrace pharma head on. Through government initiatives designed to promulgate growth in the pharmaceutical and biotech sectors, the country aims to become a top seven player and to create 20 new drugs by 2020 according to their Pharma Vision 2020.

The race for innovative competitiveness continues in Korea today, and this report aims to illustrate some of the shining examples close to the finish line." - excerpt from report introduction Weniger anzeigen

"Over the last decade, the Malaysian pharma sector has grown at a rate of between eight and ten percent per year, faster than the country's GDP over the same period. The latest WHO data for Malaysia puts spending on healthcare at four percent of GDP in 2012, lower than many developed countries but the second highest expenditure per capita in the ASEAN region. This spending is set to increase as the Malaysian government is aiming for universal coverage. At the same time, in 2010, healthcare has… Mehr anzeigen

"Over the last decade, the Malaysian pharma sector has grown at a rate of between eight and ten percent per year, faster than the country's GDP over the same period. The latest WHO data for Malaysia puts spending on healthcare at four percent of GDP in 2012, lower than many developed countries but the second highest expenditure per capita in the ASEAN region. This spending is set to increase as the Malaysian government is aiming for universal coverage. At the same time, in 2010, healthcare has been identified as one of ten National Key Economic Areas (NKEAs) with the ambition that a growing healthcare sector will help advance Malaysia into a high-income nation by 2020." - report exceprt Weniger anzeigen

"Leaders in Qatar seem supremely unworried by the effect that the rise of shale gas in the US and Canada will have on its dominance of LNG markets around the world. In February 2014, Minister of Energy of Qatar Mohamed Saleh Al-Sada, told the UK's Daily Telegraph: "we do not consider the US shale gas revolution to be a game changer but rather a validation of Qatar's strategy. Global gas demand has been growing consistently and we have had the flexibility to re-plan our LNG marketing to meet… Mehr anzeigen

"Leaders in Qatar seem supremely unworried by the effect that the rise of shale gas in the US and Canada will have on its dominance of LNG markets around the world. In February 2014, Minister of Energy of Qatar Mohamed Saleh Al-Sada, told the UK's Daily Telegraph: "we do not consider the US shale gas revolution to be a game changer but rather a validation of Qatar's strategy. Global gas demand has been growing consistently and we have had the flexibility to re-plan our LNG marketing to meet growing demand in Asia and elsewhere."

Currently, nearly 85 percent of Qatar's gas production is converted to LNG and exported through Qatargas and RasGas, Qatar's two LNG producing companies with a joint capacity of 79 Mmtpa." - report excerpt Weniger anzeigen

"We honestly feel like a member of the richest club of pharmaceutical countries,” declares Igor Radziewicz-Winnicki, undersecretary of state at the country’s Min-istry of Health. Not only is Poland the largest pharma-ceutical market in the Central & Eastern Europe region and the sixth largest in Europe (USD 8.1 billion in market value), it is also a hub for production and functional activities. With a GDP growth of 3 percent forecast by the OECD, and the first positive balance of trade in 2013… Mehr anzeigen

"We honestly feel like a member of the richest club of pharmaceutical countries,” declares Igor Radziewicz-Winnicki, undersecretary of state at the country’s Min-istry of Health. Not only is Poland the largest pharma-ceutical market in the Central & Eastern Europe region and the sixth largest in Europe (USD 8.1 billion in market value), it is also a hub for production and functional activities. With a GDP growth of 3 percent forecast by the OECD, and the first positive balance of trade in 2013 since its accession to the EU, there are also clear signs of economic momentum. However, Poland has some of the lowest prices of both innovative and generic drugs in Europe. At the same time, as cost containment measures keep the pressure on other European health authorities to reduce drug reimbursement expenditures, the Polish pharma industry is also struggling to deal with the pressure from its own 2012 re-imbursement Act while reasserting its positioning alongside the Big 5 Germany, France, Spain, Italy and the UK." - report excerpt Weniger anzeigen

"Regarded as one of the world's ultimate 'gas bounties,' Australia has long featured prominently in the minds of investors. Indeed, with eye-watering LNG mega-projects maturing the country into an energy superpower, a well-stocked pipeline of brown and greenfield options, and a dazzling array of unconventional prospects ripe for the picking, there is certainly much that appeals. "This is the only country in the world to have enjoyed 25 years of uninterrupted growth and its progressive business… Mehr anzeigen

"Regarded as one of the world's ultimate 'gas bounties,' Australia has long featured prominently in the minds of investors. Indeed, with eye-watering LNG mega-projects maturing the country into an energy superpower, a well-stocked pipeline of brown and greenfield options, and a dazzling array of unconventional prospects ripe for the picking, there is certainly much that appeals. "This is the only country in the world to have enjoyed 25 years of uninterrupted growth and its progressive business climate makes for an absolutely fantastic place to invest," affirms François Romanet, president of the French Australian Chamber of Commerce and Industry." - report excerpt Weniger anzeigen